Early intubation and decreased in-hospital mortality in patients with coronavirus disease 2019

Ryo Yamamoto1*, Daiki Kaito1, Koichiro Homma3, Akira Endo2, Takashi Tagami3,4, Morio Suzuki5, Naoyuki Umetani5, Masayuki Yagi6, Eisaku Nashiki7, Tomohiro Suhara8, Hiromasa Nagata8, Hiroki Kabata9, Koichi Fukunaga9, Kazuma Yamakawa10, Mineji Hayakawa11, Takayuki Ogura12, Atsushi Hirayama13, Hideo Yasunaga4 and Junichi Sasaki1 on behalf of the J-RECOVER study group

Abstract

Background: Some academic organizations recommended that physicians intubate patients with COVID-19 with a relatively lower threshold of oxygen usage particularly in the early phase of pandemic. We aimed to elucidate whether early intubation is associated with decreased in-hospital mortality among patients with novel coronavirus disease 2019 (COVID-19) who required intubation.

Methods: A multicenter, retrospective, observational study was conducted at 66 hospitals in Japan where patients with moderate-to-severe COVID-19 were treated between January and September 2020. Patients who were diagnosed as COVID-19 with a positive reverse-transcription polymerase chain reaction test and intubated during admission were included. Early intubation was defined as intubation conducted in the setting of ≤6 L/min of oxygen usage. In-hospital mortality was compared between patients with early and non-early intubation. Inverse probability weighting analyses with propensity scores were performed to adjust patient demographics, comorbidities, hemodynamic status on admission and time at intubation, medications before intubation, severity of COVID-19, and institutional characteristics. Subgroup analyses were conducted on the basis of age, severity of hypoxemia at intubation, and days from admission to intubation.

Results: Among 412 patients eligible for the study, 110 underwent early intubation. In-hospital mortality was lower in patients with early intubation than those with non-early intubation (18 [16.4%] vs. 88 [29.1%]; odds ratio, 0.48 [95% confidence interval 0.27–0.84]; p = 0.009, and adjusted odds ratio, 0.28 [95% confidence interval 0.19–0.42]; p < 0.001). The beneficial effects of early intubation were observed regardless of age and severity of hypoxemia at time of intubation; however, early intubation was associated with lower in-hospital mortality only among patients who were intubated later than 2 days after admission.

Conclusions: Early intubation in the setting of ≤6 L/min of oxygen usage was associated with decreased in-hospital mortality among patients with COVID-19 who required intubation.

*Correspondence: ryo.yamamoto@gmail.com
1 Department of Emergency and Critical Care Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Coronavirus disease 2019 (COVID-19) causes respiratory failure and often requires mechanical ventilation (MV) [1, 2]. Although several medications prevent disease progression and improve clinical outcomes [3–7], many patients still die following long-term MV management. Rapid deterioration of oxygenation is also a particular feature of COVID-19, impeding physicians from determining the optimal timing of intubation [8, 9].

The idea of early intubation with relatively preserved lung function arose based on early data, where the initiation of MV after developing severe acute respiratory distress syndrome (ARDS) had devastating consequences in patients with COVID-19 [10, 11]. Avoiding self-induced lung injury due to spontaneous breathing is another pathophysiological benefit of early intubation [12], although obvious favorable outcomes following such a strategy have not been validated [13]. Notably, some academic organizations recommended that physicians intubate patients with COVID-19 with a relatively lower threshold of oxygen usage, such as 6–8 L/min, without any scientific data [14, 15].

Given the potential benefit of early intubation, several studies compared different intubation times for respiratory failure due to COVID-19 and identified increased mortality and prolonged MV use in patients who were intubated in a later phase [16, 17]. However, most studies defined early intubation using days from admission to intubation, rather than the degree of preserved pulmonary function at the time of intubation; therefore, immortal time bias is a concern [18]. Moreover, the lack of patient characteristics at the time of intubation disturbs data interpretation, and it remains unclear whether the timing of initiation of MV simply reflects COVID-19 severity.

Therefore, we examined patients with COVID-19 who required intubation using a multicenter database to elucidate the clinical benefit of early intubation, which was defined as intubation for patients with a limited amount of oxygen usage. We hypothesized that early intubation is associated with decreased in-hospital mortality among patients with COVID-19.

Methods
Study design and setting
A retrospective, multicenter, observational study was conducted by the J-RECOVER study group, which was established in 2020 to investigate multiple clinical issues related to COVID-19, using data between January and September 2020 [19]. Sixty-six hospitals, where patients with moderate-to-severe COVID-19 were treated, participated in the study. Before study initiation, collaborating hospitals obtained individual local institutional review board (IRB) approval for conducting research with human subjects. This study was approved by the IRB of the Keio University School of Medicine (application number: 20200317) for conducting research with humans. The requirement for informed consent was waived because of the anonymous nature of the data used.

In Japan, after sporadic COVID-19 cases were noted in January 2020, there were two surges of newly diagnosed COVID-19 cases during the study period. During those surges, several academic organizations were concerned of nosocomial infection among healthcare providers during the invasive respiratory care of patients with COVID-19, and they recommended avoiding noninvasive positive-pressure ventilation (NIPPV) and high-flow nasal cannula (HFNC) for patients with COVID-19. Additionally, physicians at some institutions preferred to intubate patients with COVID-19 with lower thresholds of oxygen usage, such as 6–8 L/min.

Study population
We included patients who met the following three inclusion criteria: (1) diagnosis of COVID-19 with a positive reverse-transcription polymerase chain reaction (RT-PCR) result for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), (2) at least 18 years of age, and (3) intubated during admission. Patients were excluded if they were transferred from another health care facility after intubation or they were re-admitted for recurrent COVID-19 symptoms.

Data collection and definitions
Participating hospitals obtained data from medical charts and the Japanese Diagnosis Procedure Combination (DPC) records at each hospital [20]. DPC is used for administrative claims and, therefore, includes demographic data; diagnosis at admission, comorbidities, and post-admission complications that are coded with the International Classification of Diseases, 10th Revision; chronic cardiopulmonary status, including Hugh–Jones and New York Heart Association (NYHA) functional classifications; treatments provided during hospitalization, including medications, blood products, surgery, and interventional procedures, along with dose and date; and discharge abstract data. Data are recorded using a
uniform data submission format across the country, and physicians at each institution are mandated to confirm that data are correctly submitted with reference to medical charts. As DPC is a record for inpatients, data after hospital discharge are not available.

Data were also obtained from medical charts that included the following: the date of onset of COVID-19 symptoms, positive RT-PCR test, and admission; type of initial symptom; vital signs, hemodynamic score of Sequential Organ Failure Assessment (SOFA), arterial blood gas assay (i.e., pH, partial pressure of oxygen and carbon dioxide $[\text{PaO}_2 \text{ and PaCO}_2$, respectively]), and lactate value on hospital admission; intubation data, including the amount of oxygen administered immediately before intubation, Glasgow Coma Scale (GCS) andhemodynamic score of SOFA before intubation, arterial blood gas assay before and after intubation, and initial setting of MV; days of MV and NIPPV as well as usage of HFNC; prone ventilation, extracorporeal membrane oxygenation (ECMO), and reintubation; and laboratory data measured during admission. Additionally, data regarding particular medications, including but not limited to remdesivir, complications, and cause of death were obtained from medical charts to complement the DPC data.

Early intubation was defined as intubation that was conducted when the amount of oxygen administered immediately before intubation was $\leq 6$ L/min, whereas non-early intubation was defined when the amount of oxygen was $> 6$ L/min or when HFNC or NIPPV was used before intubation. The frequency of early intubation at each institution was calculated, and participating hospitals were categorized into the following three different frequencies of early intubation, using cutoff values that trisect the number of patients as equally as possible: low ($< 20\%$ of patients with COVID-19 underwent early intubation), moderate (20–40%), and high ($\geq 40\%$). Blood test on hospital admission was defined as the earliest data within 7 days after admission, whereas pre-intubation blood test was defined as the data on the day of intubation.

### Outcome measures

The primary outcome was in-hospital mortality. Secondary outcomes included hospital- and ventilator-free days to day 30 after intubation, requirement of prone ventilation and ECMO, and incidence of re-intubation. Nosocomial infection of COVID-19 due to HFNC or NIPPV usage at each institution was also included in secondary outcomes.

### Statistical analysis

Patient data were classified as early intubation and non-early intubation groups based on the timing of intubation, and unadjusted analysis was performed on the primary outcome with the Chi-square test.

Inverse probability weighting (IPW) analyses with propensity scores were performed to adjust patient background between the two groups and compare the primary and secondary outcomes [21, 22]. The propensity score was developed using a logistic regression model to estimate the probability of being assigned to the early intubation group. Relevant covariates were selected from known or possible predictors for early intubation with relatively preserved pulmonary function in patients with COVID-19 [2–5, 23, 24] and included age, sex, comorbidities (Charlson index), chronic cardiopulmonary status (Hugh–Jones and NYHA functional classifications), clinical status on admission (GCS, hemodynamic score of SOFA, and oxygen requirement), days from the onset of symptoms to intubation, pre-intubation hemodynamic score of SOFA, arterial blood gas assay before intubation, and medications for COVID-19 (corticosteroid, remdesivir, and tocilizumab) before intubation. To adjust institutional characteristics, early intubation frequency was also included in the model; patients with missing covariates were excluded. Discrimination and calibration precision of the propensity score was analyzed using the c-statistic and the Hosmer–Lemeshow goodness-of-fit test, respectively [21]. IPW analyses were then performed as adjusted analyses where the primary outcome was compared with the Chi-square test [22]. Secondary outcomes were evaluated with odds ratios (ORs) or median differences using the Hodges–Lehmann estimator.

Three sensitivity analyses were conducted to examine the robustness of primary results. We performed an instrumental variable (IV) analysis to simulate the random assignment of patients to early intubation to account for unmeasured confounding [25]. The frequency of early intubation (early intubation rate) at each institution was used as an IV to examine the relationship between early intubation and in-hospital mortality. Moreover, multivariate logistic regression analysis with the forward stepwise method was performed to confirm that the results were not dependent on the propensity score calculation. IPW with restrictions was also conducted to avoid extreme weights, where patients with a propensity score $> 0.95$ and $< 0.05$ were excluded [22].

Subgroup analyses analyzed the association between early intubation, clinical characteristics, and in-hospital mortality. IPW analyses were repeated in patient subgroups determined by age ($< 65$ vs. $\geq 65$ years), severity of hypoxemia before intubation ($< 60$ vs. $\geq 60$ mm Hg of $\text{PaO}_2$), inadequate resuscitation before intubation ($> 2$ vs. $\leq 2$ mmol/L of arterial lactate), and days from admission to intubation ($\leq 2$ vs. $\geq 3$ days).
Descriptive statistics are presented as the median (interquartile range [IQR]) or a number (percentage). Results are shown using standardized difference and 95% confidence interval (CI), and a standardized difference <0.1 was considered non-significant. The hypothesis was tested on the primary outcome in which a two-sided α threshold of 0.05 was considered statistically significant. Secondary outcomes were compared with Chi-square test or nonparametric median test as appropriate. All statistical analyses were conducted using IBM SPSS Statistics for Windows version 27.0 (IBM Corp., Armonk, NY), R Version 4.0.2 (R Foundation for Statistical Computing, Vienna, Austria), and Microsoft Excel (Microsoft Corp., Redmond, WA).

Results
Patient characteristics
Among 4700 patients with COVID-19 in the J-RECOVER database, 412 adult patients were intubated after hospital admission and were therefore eligible for this study (Fig. 1). A total of 110 (26.7%) patients underwent early intubation for whom ≥ 6 L/min of oxygen was administered immediately before intubation.

Patient characteristics are summarized in Table 1. Patients who underwent early intubation had a higher Charlson index and higher C-reactive protein and D-dimer blood levels on the day of intubation than those who did not undergo early intubation. Additionally, more patients with early intubation had a severe chronic cardiopulmonary status (Hugh–Jones classification >III and NYHA functional classification>II), ≥ 2 mmol/L of lactate at intubation, and received remdesivir and tocilizumab before intubation compared with those without early intubation. Conversely, fewer patients in the early intubation group required ≥ 4 L/min of oxygen on hospital admission. The median number of days from the onset of symptoms to intubation was 8 days in both groups, and PaO₂ before intubation was comparable between the two groups.

A propensity model to predict the assignment of patients to early intubation was developed, and the discrimination and calibration were calculated, with a c-statistic of 0.821 (0.773–0.869) and Hosmer–Lemeshow goodness of fit of  𝑝 = 0.800, respectively. Eighteen patients in the early intubation group and 39 patients in the non-early intubation group were excluded from IPW analyses due to missing covariates for propensity score calculation; hence, IPW analyses were performed for 355 patients (Fig. 1). The characteristics of patients after IPW are summarized with standardized differences in Table 1, where all covariates were successfully adjusted.

Post-intubation characteristics (Table 2) showed that patients with early intubation have a higher PaO₂/ fraction of inspired oxygen (FiO₂) (P/F) ratio and lower PaCO₂ than those without early intubation. In addition, fewer patients with early intubation had ≥ 2 mmol/L of lactate after intubation. Furthermore, although the tidal volume of MV was similarly set in both groups, the peak and mean inspiratory pressures were lower among patients with early intubation.

In-hospital mortality and secondary outcomes
In-hospital mortality was significantly lower in patients who underwent early intubation than those who did not undergo early intubation in unadjusted analysis (18% vs. 28.8%; OR, 0.48 [95% CI 0.28–0.85];  𝑝 = 0.010; Table 3). Moreover, adjusted analysis identified similar results (9.9% vs. 27.6%; OR, 0.29 [95% CI 0.19–0.44];  𝑝 < 0.001; Table 3).

Early intubation was also associated with less frequent ECMO usage (1.6% vs. 14.4%; OR, 0.10 [95% CI 0.04–0.23]; Table 3), whereas the frequency of prone ventilation was similar regardless of the timing of intubation. Furthermore, hospital- and ventilator-free days to day 30 after intubation were related to early intubation, while there were no differences in the incidence of re-intubation. Moreover, nosocomial infection of COVID-19 due to HFNC or NIPPV usage at each institution was not identified in either group (Table 3).

Sensitivity analysis using IV identified a relationship between early intubation and decreased in-hospital mortality (OR, 0.46 [95% CI 0.23–0.90]; Additional file 1: Table S1), where the early intubation rate at each institution was strongly associated with early intubation, but not with in-hospital mortality. Multivariate logistic regression and IPW with restriction similarly revealed that early intubation was associated with decreased in-hospital mortality (OR, 0.38 [95% CI 0.24–0.60] and OR, 0.49 [95% CI 0.32–0.77], respectively; Additional file 1: Table S1).

Subgroup analysis
In subgroup analyses (Table 4), a relationship between reduced in-hospital mortality and early intubation was observed in several subgroups, namely elderly (≥ 65 years) and non-elderly adults (< 65 years) and severe hypoxemia before intubation (PaO₂< 60 mm Hg) and non-severe hypoxemia (PaO₂≥ 60 mm Hg).

Conversely, patients with ≤ 2 mmol/L of pre-intubation lactate have comparable mortality regardless of intubation timing, whereas those patients with ≥ 2 mmol/L of lactate have significantly lower in-hospital mortality when they underwent early intubation. Moreover, when patients were intubated within 2 days after hospital admission, in-hospital mortality was similar between groups; however, when they were intubated later than
2 days, early intubation was associated with decreased in-hospital mortality.

**Discussion**

In this study, early intubation in a setting of $\leq 6$ L/min of oxygen usage was associated with decreased in-hospital mortality among patients with COVID-19 who underwent intubation. Importantly, this relationship remained after adjusting for patient background and disease severity at the time of intubation; multiple sensitivity analyses also confirmed the robustness of our results.

Several pathophysiological mechanisms underlying the relationship between early intubation and reduced in-hospital mortality can be considered. First, the early initiation of positive-pressure ventilation prevents alveolar injury caused by the negative pressure of spontaneous breathing. Among patients with hypoxemic respiratory failure, including ARDS, patient self-induced lung injury...
| Characteristic                                           | Before IPW | After IPW | Standardized difference |
|---------------------------------------------------------|------------|-----------|-------------------------|
| Cases, n                                                | 110        | 302       |                         |
| Age, years, median (IQR)                                | 67 (54–74) | 67 (57–76) | 0.082                   |
| Sex, male, n (%)                                        | 79 (71.8%) | 247 (81.8%) | 0.238                   |
| Comorbidity, Charlson index, median (IQR)               | 0 (0–1)    | 0 (0–1)   | 0.122                   |
| Comorbidity, chronic lung disease, n (%)                | 1 (0.9%)   | 0 (0.0%)  | 0.136                   |
| Comorbidity, diabetes, n (%)                            | 31 (28.2%) | 76 (25.2%) | 0.068                   |
| Chronic cardiopulmonary status                         |            |           |                         |
| Hugh–Jones classification, > III, n (%)                 | 20 (18.2%) | 39 (12.9%) | 0.146                   |
| NYHA functional classification, > II, n (%)             | 1 (0.9%)   | 0 (0.0%)  | 0.136                   |
| Status on hospital arrival                              |            |           |                         |
| GCS, median (IQR)                                       | 15 (15–15) | 15 (15–15) | 0.098                   |
| Respiratory rate, /min, median (IQR)                    | 22 (18–27) | 24 (20–28) | 0.106                   |
| Oxygen requirement, ≥ 4 L/min, n (%)                    | 50 (58.1%) | 171 (70.4%) | 0.259                   |
| SOFA, hemodynamic score, median (IQR)*                  | 0 (0–0)    | 0 (0–0)   | 0.219                   |
| SOFA on ICU admission, total score, median (IQR)        | 6 (4–8)    | 6 (4–9)   | 0.203                   |
| Status at intubation                                    |            |           |                         |
| Days from onset of symptoms, median (IQR)               | 8 (5–10)   | 8 (6–10)  | 0.101                   |
| PaO2, mm Hg, median (IQR)                               | 70 (59–81) | 69 (58–87) | 0.046                   |
| SOFA, hemodynamic score, median (IQR)*                  | 0 (0–0)    | 0 (0–0)   | 0.206                   |
| Lactate, ≥ 2 mmol/L, n (%)                              | 6 (37.5%)  | 5 (15.6%) | 0.511                   |
| Blood test at intubation                                |            |           |                         |
| WBC, 10³/μL                                             | 6.8 (4.7–8.5) | 6.8 (5.2–9.5) | 0.048                   |
| CRP, mg/dL                                              | 11 (5–15)  | 10 (7–14) | 0.150                   |
| D-dimer, μg/dL                                          | 2.0 (1.1–4.7) | 1.8 (0.8–2.9) | 0.387                   |
| Medications, n (%)                                      |            |           |                         |
| Remdesivir                                              | 37 (33.6%) | 64 (21.2%) | 0.282                   |
| Tocilizumab                                             | 9 (8.2%)   | 7 (2.3%)  | 0.265                   |
| Dexamethasoneb                                          | 28 (25.5%) | 78 (25.8%) | 0.009                   |
| Respiratory support before intubation, n (%)            |            |           |                         |
| HFNC                                                    | 0 (0.0%)   | 25 (8.3%) | 0.425                   |
| NIPPV                                                   | 0 (0.0%)   | 1 (0.3%)  | 0.062                   |
| Frequency of early intubation, n (%)                    |            |           |                         |
| Low                                                     | 6 (5.5%)   | 132 (43.7%) | 0.992                   |
| Moderate                                                | 43 (39.1%) | 115 (38.1%) | 0.021                   |
| High                                                    | 61 (55.5%) | 55 (18.2%) | 0.837                   |
| Days from arrival to intubation, days, median (IQR)     | 0 (0–3)    | 0 (0–2)   | 0 (0–1)                 |
Table 1 (continued)

COVID-19 coronavirus disease 2019, IPW inverse probability weighting, IQR interquartile range, NYHA New York Heart Association, GCS Glasgow Coma Scale, SOFA Sequential Organ Failure Assessment, ICU intensive care unit, PaO₂ partial pressure of oxygen, WBC white blood cell count, CRP C-reactive protein, HFNC high-flow nasal cannula, NIPPV noninvasive positive-pressure ventilation

* The hemodynamic score of SOFA is on a scale of 0 to 4, where 0 indicates ≥ 70 mm Hg of mean arterial pressure

b Other corticosteroids equivalent to 6 mg of dexamethasone (or at least half dose of it) are included

Table 2 Characteristics of COVID-19 patients after intubation

| Arterial blood gas assay                  | Early intubation | Non‑early intubation | Standardized difference |
|------------------------------------------|------------------|----------------------|-------------------------|
| P/F ratio, median (IQR)                  | 195 (167–299)    | 159 (132–211)        | 0.654                   |
| PaO₂, mm Hg, median (IQR)                | 120 (94–156)     | 96 (77–137)          | 0.233                   |
| pH, median (IQR)                         | 7.37 (7.33–7.41) | 7.36 (7.31–7.41)     | 0.000                   |
| PaCO₂, mm Hg, median (IQR)               | 40 (38–42)       | 43 (37–48)           | 0.483                   |
| Lactate, ≥ 2 mmol/L, n (%)               | 17 (4.6%)        | 24 (7.1%)            | 0.108                   |

MV setting, median (IQR)

| FiO₂                                      | 0.5 (0.5–0.7) | 0.6 (0.5–1.0) | 0.509 |
|-------------------------------------------|---------------|---------------|-------|
| Tidal volume, mL                          | 450 (400–480) | 430 (380–500) | 0.012 |
| Respiratory rate, breaths/min             | 18 (15–20)    | 16 (15–20)    | 0.196 |

MV measurements, median (IQR)

| Peak inspiratory pressure, cmH₂O         | 23 (20–24)    | 24 (21–27)    | 0.437 |
| Mean inspiratory pressure, cmH₂O         | 14 (11–15)    | 14 (12–16)    | 0.130 |

The numbers in the table were adjusted by weighing with propensity scores

COVID-19 coronavirus disease 2019, IQR interquartile range, P/F PaO₂/FiO₂, PaO₂ partial pressure of oxygen, PaCO₂ partial pressure of carbon dioxide, FiO₂ fraction of inspired oxygen, MV mechanical ventilation

Table 3 Early intubation and clinical outcomes

| In-hospital mortality                     | Early intubation | Non‑early intubation | p value | OR (95% CI) | Difference in median (95% CI) |
|------------------------------------------|------------------|----------------------|---------|-------------|-----------------------------|
| Unadjusted, n/total (%)                  | 18/110 (16.4%)   | 87/302 (28.8%)       | 0.010   | 0.48 (0.28–0.85) | 0.10 (0.08–0.13) |
| IPW analysis, % (95% CI)                 | 9.9% (6.9–12.9%) | 27.6% (22.9–32.2%)   | < 0.001 | 0.29 (0.19–0.44) | 3 (1–5) |
| Hospital-free days to day 30 after intubation, days, median (IQR) | 23 (16–27) | 14 (0–25) | < 0.001 | 0.0 (0–1) | 0 (0–1) |
| Ventilator-free days to day 30 after intubation, days, median (IQR) | 5 (0–14) | 1 (0–15) | 0.010 | 0 (0–2) |
| Requirement of prone ventilation, % (95% CI) | 28.8% (23.8–33.8%) | 33.4% (28.3–38.6%) | 0.206 | 0.81 (0.58–1.13) |
| Requirement of ECMO, % (95% CI)          | 1.6% (0.3–2.9%)  | 14.4% (10.8–18.1%)   | < 0.001 | 0.10 (0.04–0.23) |
| Re-intubation, % (95% CI)                | 10.6% (7.3–14.0%)| 7.7% (4.3–11.2%)     | 0.244   | 1.42 (0.78–2.58) |
| Nosocomial infection of COVID-19 due to HFNC/NIPPV, per institution, n/total (%) | | | | | |
| Pre-intubation usage                     | 0/16 (0.0%)     | 0/5 (0.0%)          |         |             |
| Post-intubation usage                    | 0/2 (0.0%)      | 0/5 (0.0%)          |         |             |

OR odds ratio, CI confidence interval, IPW inverse probability weighting, IQR interquartile range, HFNC high-flow nasal cannula, NIPPV noninvasive positive-pressure ventilation, MV mechanical ventilation, ECMO extracorporeal membrane oxygenation, COVID-19 coronavirus disease 2019
happens by high transpulmonary pressure due to spontaneous inspiratory drive [12, 26, 27]. An animal study also reported that spontaneous breathing caused overstretch of the dependent lung, followed by alveolar injuries [28, 29]. Notably, patients with non-early intubation in this study had more severe lung injury (i.e., lower post-intubation PaO2, higher PaCO2, and higher peak and mean inspiratory pressures), whereas pre-intubation PaO2 was comparable between early and non-early intubation groups. Considering that patients with COVID-19 who require MV frequently present with vigorous spontaneous breathing [2, 30], early lung-protective ventilation may further mitigate alveolar injury in this study.

Second, oxygenation deterioration during intubation affects the survival of patients with COVID-19. Prolonged hypoxemia after intubation was reported in patients with severe COVID-19 [31], and the post-intubation P/F ratio was lower in patients with non-early intubation in this study, suggesting that aerated lung tissue was considerably reduced in such a population. Further, insufficient preoxygenation during intubation contributes to unfavorable outcomes in patients with non-early intubation [32].

Third, given that fewer patients with early intubation had >2 mmol/L of lactate after intubation than those with non-early intubation, early intubation may minimize the hemodynamic instability of patients with severe COVID-19. As lung injury progression increases the positive pressure needed to open the collapsed lung [27, 28], MV usage for relatively preserved lung tissue among patients with early intubation may have less disturbance on the hemodynamic stability. In addition, this speculation would be reflected in the results of subgroup analyses, in which only patients with >2 mmol/L of pre-intubation lactate benefited from early intubation. Hemodynamic disturbance during non-early intubation might have been manifested only among patients with preexisting hemodynamic instability.

Patient who underwent early intubation had higher number of hospital- and ventilator-free days, while requirement of prone ventilation and incidence of reintubation did not differ between early and non-early intubation groups. However, these results need to be interpreted with caution because the study size is limited. It should be emphasized that nosocomial infection of COVID-19 from HFNC or NIPPV usage was identified in this study population.

Most previous studies on early versus delayed intubation defined “early” as within 24–48 h after hospital admission and reported potential benefits of an early intubation strategy [16, 33, 34]. However, these retrospective studies introduced considerable discussion because the definition of early intubation by the timing during hospital stay may reflect the rapidness of disease exaggeration, rather than the treatment strategy. The present study defined patients based on oxygen usage at the time of intubation, and reduced in-hospital mortality was found in patients with early intubation after adjusting for disease severity, degree of inflammation, and cardiopulmonary status at intubation. Furthermore, this benefit was observed only when patients were intubated later than 2 days after admission, suggesting that patients who needed intubation within 48 h after admission have unique features. Considering the results in this study, early intubation should be further investigated as a useful strategy in patients with COVID-19.

Our results must be interpreted within the context of the study design. We retrospectively retrieved data, which
do not record the indications of early intubation instead of non-early intubation. Therefore, our results may differ if the decision of early intubation with relatively preserved pulmonary function is dependent on unrecorded strong prognostic factors, such as the quality of critical care. However, it should be emphasized that IV analysis was conducted as a sensitivity analysis and the association between early intubation and decreased in-hospital mortality was revealed even after unmeasured confounders were adjusted. Another limitation is that details of clinical information related to early intubation, including the degree of lung injury and transient hypoxia at the intubation, were not available. Although the post-intubation P/F ratio and inspiratory pressures were recorded, the potential consequences of such parameters following early and non-early intubation cannot be evaluated on the basis of objective data. In addition, while work of breathing may influence decision for early intubation, we were not able to incorporate this into our model due to the absence of respiratory rate or respiratory rate oxygenation (ROX) index in our database. Moreover, we investigated only patients who required intubation. Considering that some patients who did not undergo early intubation could recover from respiratory failure and avoid intubation, our result may overestimate the beneficial effect of early intubation. Finally, as this study included patients in early months of the pandemic year, few patients used HFNC/NIPPV. Therefore, superiority of early intubation to HFNC/NIPPV was not examined in this study and our results do not deny the usefulness of HFNC/NIPPV for patients with COVID-19. Given that HFNC/NIPPV has been shown to effectively prevent intubation in patients with COVID-19[35, 36], as well as that early intubation strategy would deplete valuable resources including ventilator, early intubation should be carefully considered in daily practice. A properly designed study is mandated to validate that early intubation before critical exaggeration of lung function is a viable treatment option in COVID-19.

Conclusions
We revealed that early intubation in the setting of \( \leq 6 \) L/min of oxygen usage was associated with decreased in-hospital mortality among patients with COVID-19 who required intubation. Relatively earlier intubation before pulmonary function is devastated due to COVID-19 should be further validated in future studies.

Abbreviations
COVID-19: Coronavirus disease 2019; MV: Mechanical ventilation; ARDS: Acute respiratory distress syndrome; IRB: Institutional review board; NIPPV: Noninvasive positive-pressure ventilation; HFNC: High-flow nasal cannula; RT-PCR: Positive reverse-transcription polymerase chain reaction; SARS-CoV-2: Severe acute respiratory syndrome coronavirus-2; DPC: Diagnosis procedure combination; NYHA: New York Heart Association; SOFA: Sequential Organ Failure Assessment; PaO\(_2\): Partial pressure of oxygen; PaCO\(_2\): Partial pressure of carbon dioxide; GCS: Glasgow Coma Scale; ECMO: Extracorporeal membrane oxygenation; IPW: Inverse probability weighting; IQR: Interquartile range; CI: Confidence interval.

Supplementary information
The online version contains supplementary material available at https://doi.org/10.1186/s13054-022-03995-1.

Additional file 1: Table S1. In-hospital mortality in sensitivity analyses.

Acknowledgements
Not applicable.

Author contributions
RY, DK, KH, AE, TT, MS, NU, and JS designed the study. RY, DK, and TT performed data collection. KY, MH, TO, AH, HY, and JS managed quality control. RY, AE, TT, MY, and EN performed data analysis and data interpretation. RY, TS, HN, HK, HF, and JS performed writing and critical revision. All authors revised the article. All authors read and approved the final manuscript.

Funding
There is no funding source in this study.

Availability of data and materials
The data of this study are available from the J-RECOVER study group; however, restrictions apply to the availability of these data, which were used under the license for the current study and so are not publicly available. However, data are available from the authors upon reasonable request and with permission of the J-RECOVER study group.

Declarations
Ethics approval and consent to participate
This study was approved by the IRB of the Keio University School of Medicine (application number: 20200317) for conducting research with humans. The requirement for informed consent was waived because of the anonymous nature of the data used.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1Department of Emergency and Critical Care Medicine, Keio University School of Medicine, Tokyo, Japan. 2Department of Emergency and Critical Care Medicine, Yokohama City Minato Red Cross Hospital, Yokohama, Kanagawa, Japan. 3Department of Emergency and Critical Care Medicine, Tokyo Medical and Dental University Hospital, Tokyo, Japan. 4Department of Emergency and Critical Care Medicine, Nippon Medical School Musashikosugi Hospital, Kawasaki, Kanagawa, Japan. 5Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo, Tokyo, Japan. 6Department of Emergency and Critical Care Medicine, Kawasaki General Hospital, Tokyo, Japan. 7Emergency Medicine and Acute Critical Care Center, Tokyo Medical and Dental University Hospital, Tokyo, Japan. 8Department of Clinical and Acute Care Surgery, Matsudo City General Hospital, Chiba, Japan. 9Department of Emergency and Critical Care Medicine, Yokohama City Minato Red Cross Hospital, Yokohama, Kanagawa, Japan. 10Department of Anaesthesiology, Keio University School of Medicine, Tokyo, Japan. 11Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. 12Department of Emergency Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan. 13Department of Emergency Medicine, Hokkaido University Hospital, Sapporo, Hokkaido, Japan. 14Department of Emergency Medicine and Critical Care Medicine, Tochigi Prefectural Emergency and Critical Care Centre, Imperial Foundation Saiseikai Utsunomiya Hospital, Tchigi, Japan. 15Public Health, Department of Social Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
References

1. Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle region—case series. N Engl J Med. 2020;382:1022–1022.

2. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5,700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323:2052.

3. Abani O, Abbas A, Abbas F, Abbas M, Abbasi S, Abbass H, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:1637–45.

4. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of covid-19—final report. N Engl J Med. 2020;383:1813–26.

5. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19. JAMA. 2020;324:1307.

6. Limen RY, Sedono R, Sugianto A, Harroyanto TI. Janus kinase (JAK)-inhibitors and coronavirus disease 2019 (COVID-19) outcomes: a systematic review and meta-analysis. Expert Rev Anti Infect Ther. 2021;19:61–10.

7. Hartyanto TI, Intan D, Hananto JE, Harapan H, Kurniawan A. Vitamin D supplementation and COVID-19 outcomes: a systematic review, meta-analysis and meta-regression. Rev Med Virol. 2021;32:e2269.

8. Azouly E, Belouca S, Guidet B, Pateron D, Vivien B, Le Dorze M. Admission decisions to intensive care units in the context of the major COVID-19 outbreak: local guidance from the COVID-19 Paris-region area. Crit Care. 2020. https://doi.org/10.1186/s13054-020-03021-2.

9. Belongie F, Studer A, Seegers V, Richard J, Desprez C, Fage N, et al. Longitudinal changes in compliance, oxygenation and ventilatory ratio in COVID-19 versus non-COVID-19 pulmonary acute respiratory distress syndrome. Crit Care. 2021;25:1–10.

10. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infection pneumonia in Wuhan, China. JAMA. 2020;323:1061.

11. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239.

12. Marin JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020;323:2329–30.

13. Tobin MJ, Laghi F, Jubran A. P-SILI is not justification for intubation of COVID-19 patients. Ann Intensive Care. 2020;10:105.

14. Chang D, Xu H, Rebaa A, Sharma L, Della Cruz CS. Protecting healthcare workers from subclinical coronavirus infection. Lancet Respir Med. 2020;8:113.

15. Niederman MS, Richeldi L, Chotirmall SH, Bai C. Raising to the challenge of COVID-19: advice for pulmonary and critical care and an agenda for research. Am J Respir Crit Care Med. 2020;201:1019–22.

16. Pandya A, Kaut NA, Sacher D, O'Connor G, Salerno D, Desai P, et al. Ventilatory mechanics in early vs late intubation in a cohort of coronavirus disease 2019 patients with ARDS: a single center's experience. Chest. 2021;159:653–6.

17. Fayed M, Patel N, Yeldo N, Nowak K, Penning DH, Vasconcelos Torres F, et al. Effect of intubation timing on the outcome of patients with severe respiratory distress secondary to COVID-19 pneumonia. Cureus. 2021;13:e19620.

18. Hong L. Immortal time bias in comparing late vs early intubation in patients with coronavirus disease 2019. Chest. 2021;159:1679–80.

19. Takashi T, Kuzuma Y, Akira E, Mineji H, Takahito O, Atsushi H, et al. Japanese multicenter research of COVID-19 by assembling real-world data: a study protocol. Ann Clin Epidemiol. 2022. https://doi.org/10.37737/ace.2022

20. Tagami T, Matsui H, Fushimi K, Yasunaga H. Intravenous immunoglobulin in use in septic shock patients after emergency laparotomy. J Infect. 2015;71:1158–66.

21. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res. 2011;46:399–424.

22. Austin PC, Stuart EA. The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res. 2017;26:1654–70.

23. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med. 2020;180:1081.

24. Zanella A, Fionio G, Antonelli M, Bellani G, Berselli A, Bove T, et al. Time course of risk factors associated with mortality of 1260 critically ill patients with COVID-19 admitted to 24 Italian intensive care units. Intensive Care Med. 2021;47:995–1008.

25. Ashana DC, Umscheid CA, Stephens-Shields AJ, Kohn R, Maddren V, Harhay MO, et al. Determining the association between end-of-life care resources and patient outcomes in Pennsylvania ICUs. Crit Care Med. 2019;47:1501–8.

26. Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L, et al. COVID-19 pneumonia: Different respiratory treatments for different phenotypes? Intensive Care Med. 2020;46:1099–102.

27. Pelosi P, Andreoli L, Vitale G, Pesenti A, Gattinoni L. Vertical gradient of regional lung inflation in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1994;149:88–13.

28. Brochard L, Slutsky A, Pesenti A. Mechanical ventilation to minimize progression of lung injury in acute respiratory failure. Am J Respir Crit Care Med. 2017;195:438–42.

29. Yoshida T, Toriani V, Gomes S, De Santis RR, Beraldo MA, Costa EL, et al. Spontaneous effort causes occult pendelluft during mechanical ventilation. Am J Respir Crit Care Med. 2013;188:1420–7.

30. Rola P, Farkas J, Spiegel R, Kyle-Sidell C, Weingart S, Duggan L, et al. Rethinking the early intubation paradigm of COVID-19: Time to change gears? Clin Exp Emerg Med. 2020;7:78–80.

31. D’Amore J, Meigher S, Patterson E, Sanapala S, Tarr M, Leisman D, et al. Intubation outcomes and practice trends during the initial New York SARS-COV-19 surge at an academic, level 1 trauma, urban emergency department. J Am Coll Emerg Physicians Open. 2021;2:e12563.

32. Baillard C, Boubaya M, Statescu E, Collet M, Solis A, Guezennec J, et al. Incidence and risk factors of hypoxaemia after preoxygenation at induction of anaesthesia. Br J Anaesth. 2019;122:388–94.

33. Siempos II, Xourgia E, Ntaidou TK, Zervakis D, Magira EE, Kotanidou A, et al. Effect of early vs. delayed or no intubation on clinical outcomes of patients with COVID-19: an observational study. Front Med Lausanne. 2020;7:614.

34. Villarreal-Fernandez E, Patel R, Golamani R, Khalid M, DeWaters A, Haozui P. A plea for avoiding systematic intubation in severely hypoxic patients with COVID-19-associated respiratory failure. Crit Care. 2020;24:337.

35. Ospona-Tascon GA, Calderon-Tapia LE, Garcia AF, Zarama V, Gomez-Alvarez F, Alvarez-Saa T, et al. Effect of high-flow oxygen therapy vs conventional oxygen therapy on invasive mechanical ventilation and clinical recovery in patients with severe COVID-19: a randomized clinical trial. JAMA. 2021;326:2161–71.

36. Perkins GD, Ji C, Connolly BA, Couper K, Lall R, Bailie JK, et al. Effect of noninvasive respiratory strategies on intubation or mortality among patients with acute hypoxic respiratory failure and COVID-19: the RECOVERY-PS randomized clinical trial. JAMA. 2022;327:546–58.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.